

Funded Study: Treatment of Canine Osteosarcoma.

Study Title: Evaluation of Orally Administered PARP inhibitor Olaparib in the Adjuvant Setting with Carboplatin in Dogs with Solid Tumors.

Purpose of Study:

Greater than 80% of dogs diagnosed with osteosarcoma (OSA) have microscopic disseminated disease at presentation and will die from metastatic progression within 2 years of diagnosis regardless of treatment. Strong justification exists for discovering effective systemic therapies to improve outcomes in pet dogs diagnosed with OSA. Dogs in this trial will receive carboplatin and adjuvant olaparib and would be expected to have improved tumor cell killing and progression-free survival times in comparison to pet dogs treated with conventional single-agent carboplatin therapy.

Inclusion Criteria:

- Dogs with confirmed diagnosis of osteosarcoma by cytology (with a positive alkaline phosphatase stain) or histopathology
- The primary tumor must be surgically resectable via amputation
- Dogs must have chest x-rays that confirm there is no metastatic disease and cytology confirming there is not metastasis to the regional lymph node
- NO treatment with any previous chemotherapy, radiation, immunotherapy, or bisphosphonates.
- NO treatment with radiation therapy or systemic chemotherapy
- NO treatment with any immunosuppressive/homeopathic/alternative therapy including prednisone, cyclosporine or other immunomodulator agents

Eligibility Diagnostics:

Prior to study entry, pet owners will be charged an initial consultation fee and be financially responsible and required to have the following diagnostics performed on their dog:

- 1) Diagnosis of osteosarcoma via histopathology or cytology, if not already documented
- 2) Screening blood work and urinalysis, if not performed within 7 days
- 3) Chest x-rays to confirm no evidence of metastatic disease

Treatment:

Once the patient is deemed eligible patients will receive amputation. Two weeks following amputation dogs will receive carboplatin and Olaparib once every three weeks

for four treatments. Olaparib during this time period will be give twice daily for seven days starting with each carboplatin treatment. Following therapy dogs will be monitored every month to two months and will receive Olaparib twice daily throughout the monitoring.

Compensation:

This is a partially funded study upon patient eligibility and enrollment. Prior to confirmed enrollment, pet owners are financially responsible for all diagnostics such as blood work, cytology, imaging required for their pets to be deemed eligible for study recruitment. After enrollment, owners are responsible for the cost of amputation, along with exam fees, bloodwork and recheck imaging. The clinical trial will cover the cost of carboplatin and the administration fees and the cost of Olaparib.

Contact Information:

Please feel free to contact our Clinical Trials Coordinator, Rebecca Kamerer, at (217) 300-6453 or rmoss81@illinois.edu to refer a patient or for any additional information. Referring veterinarian and client calls are welcome.

